[PMID: 23563705] PubMed record related to this compound for laboratory literature review
Modalit d'uso: 5 ml al giorno (1/3 di fiala)
Mitochondrial complex I promotes kidney cancer metastasis
Key safety concerns include: Pharmacokinetic interactions: Two peptides administered together particularly via injection may alter each other's absorption, distribution, metabolism, or excretion in unpredictable ways
No statements made on this website or within any product description have been evaluated by the FDA
Drugs with a high risk of causing SJS/TEN are anti-infective sulfonamides, anti-epileptic drugs, non-steroidal anti-inflammatory drugs of the oxicam type, allopurinol, nevirapine, and chlormezanone